Benefit of targeted lung cancer therapy confirmed
Links shared publicly online about this topic.
- 245total visits
Benefit of targeted lung cancer therapy confirmed
View full resource at eurekalert.org
Tags: Cancer, Lung Cancer, Lung, Drug, Clinical Trial, Oncology
Most Recently Shared on June 4, 2011 at 5:42 am By:
Benefit of targeted lung cancer therapy confirmed: ( University of Colorado Denver ) A drug that targets a speci... http://bit.ly/jDjgeT
Also Shared By:
LCMC finds 9.6% of lung cancer patients with ALK rearrangement
news-medical.net — “ALK rearrangement has been found in 9.6% of lung cancer patients tested in the Lung Cancer Mutation Consortium, and MET amplification in another 4.1%, reflecting how many patients might benefit from targeted therapies such as crizotinib, according to research presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer.” View full resource at news-medical.net
Most Recently Shared on July 5, 2011 at 10:52 am By:
LCMC finds 9.6% of lung cancer patients with ALK rearrangement: ALK rearrangement has been found in 9.6% of lung... http://bit.ly/iDIrPh
ALK rearrangement found in nearly 10 percent of patients in Lung Cancer Mutation Consortium
eurekalert.org — “ALK rearrangement has been found in 9.6 percent of lung cancer patients tested in the Lung Cancer Mutation Consortium, and MET amplification in another 4.1 percent, reflecting how many patients might benefit from targeted therapies such as crizotinib, according to research presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer.” View full resource at eurekalert.org
Most Recently Shared on July 5, 2011 at 10:26 am By:
ALK rearrangement found in nearly 10 percent of patients in Lung Cancer Mutation Consortium: ( International Ass... http://bit.ly/mEJaJ5
LCMC finds 9.6% of lung cancer patients with ALK rearrangement
news-medical.net — “ALK rearrangement has been found in 9.6% of lung cancer patients tested in the Lung Cancer Mutation Consortium, and MET amplification in another 4.1%, reflecting how many patients might benefit from targeted therapies such as crizotinib, according to research presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer.” View full resource at news-medical.net
Most Recently Shared on July 5, 2011 at 9:27 am By:
Lung Cancer News: LCMC finds 9.6% of lung cancer patients with ALK rearrangement: ALK rearrangement has been fou... http://bit.ly/jpdsTm
ALK rearrangement found in nearly 10 percent of patients in Lung Cancer Mutation Consortium
medicalxpress.com — “ALK rearrangement has been found in 9.6% of lung cancer patients tested in the Lung Cancer Mutation Consortium, and MET amplification in another 4.1%, reflecting how many patients might benefit from targeted therapies such as crizotinib, according to research presented at the 14th World Conference on ...” View full resource at medicalxpress.com
Most Recently Shared on July 5, 2011 at 8:50 am By:
PhysOrg Health News Health News
ALK rearrangement found in nearly 10 percent of patients in Lung Cancer Mutation Consortium http://tw.medicalxpress.com/229060183
Potential new drug therapies targeting genetic mutations benefit lung-cancer patients
news-medical.net — “Some lung-cancer patients at UT Southwestern Medical Center are responding well to potential new drug therapies targeting genetic mutations. Their participation in a national study is helping to forge new avenues to attack the disease.” View full resource at news-medical.net
Most Recently Shared on June 16, 2011 at 5:23 am By:
Potential new drug therapies targeting genetic mutations benefit lung-cancer patients: Some lung-cancer patients... http://bit.ly/kM3V5T
Clinical Trial Confirms Benefit Of Targeted Lung Cancer Therapy
medicalnewstoday.com — “A drug that targets a specific type of lung cancer shows a dramatic response in more than half of the people who take it. The drug, called crizotinib, has been in clinical trials since 2006, and t” View full resource at medicalnewstoday.com
Most Recently Shared on June 5, 2011 at 10:05 am By:
MNT Clinical Trials Health News
Clinical Trial Confirms Benefit Of Targeted Lung Cancer Therapy http://mnt.to/3WLV #clinicaltrials
Medical oncologists confirm benefits of crizotinib in ALK positive lung cancer
news-medical.net — “A drug that targets a specific type of lung cancer shows a dramatic response in more than half of the people who take it. The drug, called crizotinib, has been in clinical trials since 2006, and the results from the largest group of patients to take it within the first of these clinical trials are being presented at the annual meeting of the American Society of Clinical Oncology.” View full resource at news-medical.net
Most Recently Shared on June 4, 2011 at 5:42 am By:
Medical oncologists confirm benefits of crizotinib in ALK positive lung cancer: A drug that targets a specific t... http://bit.ly/l6duZ8
Benefit of targeted lung cancer therapy confirmed
sciencedaily.com — “A drug that targets a specific type of lung cancer shows a dramatic response in more than half of the people who take it. The drug, called crizotinib, has been in clinical trials since 2006, researchers are now reporting the results from the largest group of patients to take it within the first of these clinical trials.” View full resource at sciencedaily.com
Most Recently Shared on June 3, 2011 at 8:16 pm By:
Benefit of targeted lung cancer therapy confirmed: A drug that targets a specific type of lung cancer shows a dramatic.. http://dld.bz/acfTb
New targeted therapy adds benefit to erlotinib in some patients with advanced l... ( A subset of lung cancer patients see...)
bio-medicine.org — “...A subset of lung cancer patients seem to live longer and experience de...Dr David Spigel Director of lung cancer research for the Sarah Cannon...The study included 128 patients with advanced non-small cell lung canc... MET is an important switch in cancer cells Dr Spigel explained. Wh...,New,targeted,therapy,adds,benefit,to,erlotinib,in,some,patients,with,advanced,lung,cancer,biological,biology news articles,biology news today,latest biology news,current biology news,biology newsletters” View full resource at bio-medicine.org
Most Recently Shared on October 17, 2010 at 8:18 pm By:
New targeted therapy adds benefit to erlotinib in some patients with advanced lung cancer http://j.mp/c1abZs
In Some Patients With Advanced Lung Cancer, New Targeted Therapy Adds Benefit To Erlotinib
medicalnewstoday.com — “A subset of lung cancer patients seem to live longer and experience delays in disease progression when a new drug that targets a cancer-associated molecule called MET is added to treatment with er” View full resource at medicalnewstoday.com
Most Recently Shared on October 12, 2010 at 12:05 pm By:
In Some Patients With Advanced Lung Cancer, New Targeted Therapy Adds Benefit To Erlotinib http://mnt.to/3L3n #lungcancer
New targeted therapy adds benefit to erlotinib in some patients with advanced lung cancer
news-medical.net — “A subset of lung cancer patients seem to live longer and experience delays in disease progression when a new drug that targets a cancer-associated molecule called MET is added to treatment with erlotinib, the results of a double-blind Phase-II trial show.” View full resource at news-medical.net
Most Recently Shared on October 12, 2010 at 3:26 am By:
New targeted therapy adds benefit to erlotinib in some patients with advanced lung cancer: A subset of lung cancer... http://bit.ly/bpsSiA
New targeted therapy adds benefit to erlotinib in some patients with advanced lung cancer
eurekalert.org — “A subset of lung cancer patients seem to live longer and experience delays in disease progression when a new drug that targets a cancer-associated molecule called MET is added to treatment with erlotinib, the results of a double-blind Phase II trial show.” View full resource at eurekalert.org
Most Recently Shared on October 9, 2010 at 2:44 pm By:
New targeted therapy adds benefit to erlotinib in some patients with advanced lung cancer: ( European Society for ... http://bit.ly/co3dRj
New targeted therapy adds benefit to erlotinib in some patients with advanced lung cancer
physorg.com — “A subset of lung cancer patients seem to live longer and experience delays in disease progression when a new drug that targets a cancer-associated molecule called MET is added to treatment with erlotinib, the results of a double-blind Phase-II trial show.” View full resource at physorg.com
Most Recently Shared on October 9, 2010 at 10:07 am By:
New targeted therapy adds benefit to erlotinib in some patients with advanced lung cancer http://bit.ly/aQkk8Z
Blacks Likely to Benefit From Lung Cancer Therapy - Cancer Information (Cancers, Symptoms, Treatment) on MedicineNet.com
medicinenet.com — “Information on many different cancers includes symptoms, cancer detection and prevention, and treatment options.” View full resource at medicinenet.com
Most Recently Shared on September 30, 2010 at 8:22 am By:
Blacks Likely to Benefit From Targeted Lung Cancer Therapy: Title: Blacks Likely to Benefit From Targeted Lung Can... http://bit.ly/98M2tJ
Advertisement
Lungs and Breathing
@Lung_Breathing
ALK rearrangement found in nearly 10 percent of patients in Lung Cancer Mutation Consortium: ( International Ass... http://bit.ly/mEJaJ5
1 year ago...